Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2005-09-20
2005-09-20
Novarro, Mark (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S277100, C530S300000, C530S324000, C530S350000
Reexamination Certificate
active
06946133
ABSTRACT:
The invention is a prostate specific antigen oligo-epitope peptide which comprises more than one PSA epitope peptide, which conforms to one or more human HLA class I motifs. The prostate specific antigen oligo-epitope peptide in combination with various HLA-class I molecules or interactions with various T-cell receptors elicits PSA specific cellular immune responses. The prostate specific antigen oligo-epitope peptide is useful as an immunogen in the prevention or treatment of prostatic cancer, in the inhibition of prostatic cancer cells and in the establishment and characterization of PSA-specific cytotoxic T-cell lines.
REFERENCES:
patent: 5516639 (1996-05-01), Tindall et al.
patent: 5565548 (1996-10-01), Neurath et al.
patent: 5840494 (1998-11-01), Katz et al.
patent: 5925362 (1999-07-01), Spitler et al.
patent: 0 652 014 (1995-05-01), None
patent: WO 91/02805 (1991-03-01), None
patent: WO 94/03205 (1994-02-01), None
patent: WO 94/20127 (1994-09-01), None
patent: WO 95/04548 (1995-02-01), None
patent: 9528498 (1995-10-01), None
patent: WO 95/28958 (1995-11-01), None
patent: WO 97/03203 (1997-01-01), None
Lazar et al Molecular & Cellular Biology. vol. 8 No 3 Mar. 1988 pp 1247-1252.
Burgess et al J. of Cell Biology vol. 111 Nov. 1990 pp 2129-2138.
Wathen et al (J. Gen. Virol. vol. 70. pp 2625-2635), 1989.
Salgaller et al (Cancer Immunol. Immunother. vol. 39 pp 105-116), 1994.
Cohe et al (Cancer Investigations vol. 5 pp 285-291), 1987.
Nijman et al, “Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes”,European Journal of Immunology, 1993, vol. 23: 1215-1219.
Correale, P. et al, “In Vitro Generation of Human Cytotoxic T Lymphocytes Specific for Peptides Derived From Prostate-Specific Antigen”,Journal of Cancer Institute, vol. 89, No. 4, Feb. 19, 1997, pp. 293-300.
Kurkela, R. et al, Expression of Active, Secreted Human Prostate-specific Antigen by Recombinant Baculovirus-infected Insect Cells on a Pilot-scale,Biotechnology, vol. 13, Nov. 1995, pp. 1230-1234.
Bridon et al, “Structural Comparison of Prostate-Specific Antigen and Human Glandular Kallikrein Using Molecular Modeling”,Urology, vol. 45, No. 5, May 1995, pp. 801-806.
Correale, P. et al, “Generation of human T-cell lines specific for prostate specific antigen using an oligo-epitope peptide”, 87th Annual Meeting of the Amer. Assoc. for Cancer Research, Washington, D.C., USA Apr. 20-24, 1996 andProceedings of the Amer. Assoc. for Cancer Research. vol. 37, Mar. 21, 1996, pp. 488-499, Abstract 3335.
Correale, P. et al, “In Vitro Stimulation of Human Cytotoxic T Lymphocytes Specific for Peptides Derived From Prostate Specific Antigen”, 9th International Congressof Immunol. Jul. 23-29, 1995, San Francisco, CA Abstract 3449.
Chapdelaine et al, “Southern Blot Analysis with Synthetic Oligonucleotides, Application To Prostate Protein Genes”,Int. J. Biochem., vol. 22, No. 1, pp. 75-82, 1990.
Karr et al, “Expression of Human Prostate Specific Antigen in a Transfected Murine Adenocarcinoma Cell Line: Development of a Murine Tumor Model for Immunotherapy of Prostate Cancer”,Journal of Cellular Biochemistry Supplement, 18D (Feb. 26-Apr. 17) 1994, 253, (Abstract Y511).
Karr et al, “The Presence of Prostate-specific Antigen-related Genes in Primates and the Expression of Recombinant Human Prostate-specific Antigen in a Transfected Murine Cell Line”,Cancer Research, vol. 55, No. 11, pp. 2455-2462, Jun. 1, 1995.
Bei et al, “A Recombinant Prostate Specific Antigen (PSA) Produced in a Baculovirus Expression System”,Proceedings of the Amer. Association for Cancer Res. Annual Meeting, 36(Mar.), 1995, p. 664 (Abs. 3833).
Bei et al, “Generation, Purification and Characterization of a Recombinant Source of Human Prostate-Specific Antigen”,Journal of Clinical Laboratory Analysis9:261-268 (1995).
Donovan, Jr. et al, “Immunotherapy of Prostate Cancer”,Problems in Urology, vol. 4, No. 3, pp. 489-505, Sep. 1990.
Abulafia et al, “In Vitro Production of T Cells Immunoreactive Against Prostate Specific Antigen: A Novel Approach for an Antigen-Specific Adoptive Immunotherapy Program for Prostate Cancer”, Joint Meeting of the American Society for Biochemistry and Molecular Biology,FASEB J., New Orleans, Louisiana, Jun. 4-7 1990, vol. 4(7) (Abstract 1896).
Berzofsky et al, “Immunogenicity and Antigen Structure”,Fundamental Immunology, 2nd Ed., W.E. Paul (Ed); Raven Press Ltd., New York, 1989, pp. 169-208.
Ross et al, “Adoptive Immunotherapy of Hormone-Refractory, Stage D2 Prostate Cancer using Ex Vivo Activated Autologous T Cells (Autolymphocyte Therapy): Results from a Pilot Study”,Biotechnology Therapeutics, 4(3&4), 197-211 (1993).
Sanda et al, “Demonstration of a Rational Strategy for Human Prostate Cancer Gene Therapy”,The Journal of Urology, vol. 151, 622-628, Mar. 1994.
Vieweg et al, “Immunotherapy of Prostate Cancer in the Dunning Rat Model: Use of Cytokine Gene Modified Tumor Vaccines”,Cancer Research, 54:7, p. 1760-1765, Apr. 1994.
Vieweg et al, “Efficient Gene Transfer with Adeno-associated Virus-based Plasmids Complexed to Cationic Liposomes for Gene Therapy of Human Prostate Cancer”,Cancer Research, vol. 55:11, pp. 2366-2372 (Jun.) 1995.
Hodge et al, A Recombinant Vaccinia Virsu Expressing Human Prostate-Specific Antigen (PSA): Safety and Immunogenicity in a non-Human Primate,Int. J. Cancer63, pp. 231-237 (Oct. 9) 1995.
Akdas et al, “Human Leukocyte Antigen Subtype Analysis in Patients with Advanced Adenocarcinoma of the Prostate”,The Prostate, 23:111-113 (Mar.) 1994.
Sanda et al, “Molecular Characterization of Defective Antigen Processing in Human Prostate Cancer”,J. Nat'l Cancer Institute, vol. 87:4, pp. 280-285, Feb. 1995.
Sharpe et al, “Modulated expression of human leucocyte antigen class I and class II determinants in hyperplastic and malignant human prostatic epithelium”,British Journal of Urology, (Nov.) 1994, 74, 609-616.
Walsh et al, “Molecular Characterization of Heterogeneity in Immune Evasion by Human Prostate Cancer Cells: Implications for Prostate Cancer Gene Therapy”,The Journal of Urology, vol. 151, No. 5, May 1994 (Abstract 106).
Blades et al, “Loss of HLA Class I Expression in Prostate Cancer: Implications for Immunotherapy”,Urology, vol. 46:5, p. 686-687, (Nov.) 1995.
Lundwall et al, Molecular cloning of human prostate specific antigen cDNA,FEBS Letters, vol. 214, No. 2, pp. 317-322, Apr. 1987.
Gauthier et al, Characterization of rhesus monkey prostate specific antigen cDNA,Biochimica et Biophysica Acta, 1174, pp. 207-210, 1993.
Schlom Jeffrey
Tsang Kwong-yok
Zaremba Sam
Heller Ehram LLP
Novarro Mark
The United States of America as represented by the Department of
LandOfFree
Prostate specific antigen oligo-epitope peptide does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prostate specific antigen oligo-epitope peptide, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prostate specific antigen oligo-epitope peptide will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3387627